2,136 reports of this reaction
6.1% of all MOMETASONE FUROATE AND FORMOTEROL FUMARATE DIHYDRATE reports
#3 most reported adverse reaction
DRUG DOSE OMISSION is the #3 most commonly reported adverse reaction for MOMETASONE FUROATE AND FORMOTEROL FUMARATE DIHYDRATE, manufactured by Organon LLC. There are 2,136 FDA adverse event reports linking MOMETASONE FUROATE AND FORMOTEROL FUMARATE DIHYDRATE to DRUG DOSE OMISSION. This represents approximately 6.1% of all 35,067 adverse event reports for this drug.
Patients taking MOMETASONE FUROATE AND FORMOTEROL FUMARATE DIHYDRATE who experience drug dose omission should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DRUG DOSE OMISSION is moderately reported among MOMETASONE FUROATE AND FORMOTEROL FUMARATE DIHYDRATE users, representing a notable but not dominant share of adverse events.
In addition to drug dose omission, the following adverse reactions have been reported for MOMETASONE FUROATE AND FORMOTEROL FUMARATE DIHYDRATE:
The following drugs have also been linked to drug dose omission in FDA adverse event reports:
DRUG DOSE OMISSION has been reported as an adverse event in 2,136 FDA reports for MOMETASONE FUROATE AND FORMOTEROL FUMARATE DIHYDRATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
DRUG DOSE OMISSION accounts for approximately 6.1% of all adverse event reports for MOMETASONE FUROATE AND FORMOTEROL FUMARATE DIHYDRATE, making it one of the most commonly reported side effect.
If you experience drug dose omission while taking MOMETASONE FUROATE AND FORMOTEROL FUMARATE DIHYDRATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.